A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of LG00034053 in Patients With Knee OA

Inclusion Criteria: * Patients diagnosed with primary osteoarthritis of the knee according to the ACR clinical criteria, with Kellgren-Lawrence grade 2 to 3 in the corresponding knee as determined in the X-ray test * Patients with pain in the index knee requiring NSAIDs or analgesics which sustained for at least 6 months * Patients with a score of ≥ 4 and ≤ 9 in response to question 1 (walking pain) on the WOMAC pain subscale (11-point NRS) * Patients with the subtotal score of ≥ 20 and ≤ 45 on the WOMAC pain subscale (11- point NRS) * Patients with BMI at or below 40 kg/m2 Exclusion Criteria: * Patients with chronic pain requiring continuous treatment * Patients with rheumatoid arthritis or other inflammatory arthritis * Patients with skin disorders at the administration site * Patients with clinically significant renal or cardiovascular disease or those with suspected SARS-CoV-2 infection * Patients in a medical condition which may affect the efficacy and/or safety assessment * Patients with Kellgren-Lawrence grade 4 in the contralateral knee * Patients with tense effusion * Patients having administered an opioid analgesic/ other analgesic/health functional foods, single dose of IA injection within a certain period prior to drug administration * Patients having undergone knee replacement